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➣ Although definitions vAry by jurisdiction, diseAses 
that affect approximately 1 in 2000 people are considered 
rare.
1 Canada is one of only a few developed countries 
without a national “orphan drug” program to protect 
patients with rare diseases from exorbitant drug costs. 
Public debate concerning government funding for these 
drugs is periodically stimulated by stories of patients 
who are deprived of life-sustaining therapies because of 
cost. However, most Canadians remain unaware of an-
other important disparity between common and rare-
disease care in this country: namely, the availability of 
research funding. Above and beyond worrying about ex-
pensive therapies, patients diagnosed with a rare disease 
are often surprised to learn that there is limited scientific 
knowledge about the causes and natural history of their 
condition and little or no ongoing research.
The reasons for this research gap are many. Pub-
lic funding agencies have a mandate to improve public 
health, and so naturally favour grants that address com-
mon conditions. As a result, researchers with an interest 
in a rare disease who enter open grant competitions may 
be disadvantaged by the limited population-level impact 
of their potential findings.
2,3 Furthermore, the relatively 
small numbers of people affected by a given rare disease 
make it difficult for researchers to recruit and study an 
adequate number of patients to reach scientifically valid 
conclusions. As a result, even basic knowledge about the 
diagnosis, causes, and consequences of many of these 
diseases is lacking.
3 Even when these aspects are well 
understood and drug development can be considered, the 
pharmaceutical industry often opts out on the grounds 
that development costs are difficult to recoup from the 
small number of potential users of a new drug for a rare 
disease.
4 
In most developed nations, governments have sought 
to target this inequity through legislation. Since the 
establishment  of  the  Office  of  Orphan  Products  De-
velopment  by  the  US  Food  and  Drug  Administration 
(FDA) in 1982, various national rare disease laws, poli-
cies, and programs have been established successfully in 
many countries around the world.
1,5–17 Some of the most 
notable of these are outlined in Table 1. The impact of 
these programs has been significant. Since the US Or-
phan Drug Act was passed in the United States in 1983, 
over 300 rare disease products, affecting over 14 mil-
lion Americans, have come to market, as compared with 
fewer than 10 products in the previous decade.
7 Between 
2006 and 2007, the National Institutes of Health Rare 
Diseases Clinical Research Network produced 25 publi-
cations, posters, and abstracts, launched 24 new studies 
with active recruitment, and enrolled 2357 rare disease 
subjects.
18 The first French National Plan for Rare Dis-
eases (2005–08) enabled the establishment of 132 “refer-
ence centres” (specialized national rare disease centres), 
500 “centres of competence” (regional rare disease care 
providers), new best-practice guidelines for 17 rare dis-
eases (with 24 more in preparatory stages at the time of 
the evaluation), and a compassionate-use system to en-
able orphan-drug coverage for patients.
19 The success 
of the European Union’s rare disease research funding 
initiative is exemplified by the EuroBioBank. Originally 
funded by a seed grant of €1.22 million by the EU’s fifth 
Framework Programme, this 10-country network of rare 
disease DNA, cell and tissue banks now contains 440 000 
rare disease samples, among which 7000 are sent annu-
ally to researchers around the world.
20
Patient advocacy groups have also played an import-
ant role in advancing the rare disease research agenda, 
both by lobbying for government action and by funding 
research directly. In the United States, the National Or-
ganization  for  Rare  Disorders  (NORD)  (www.raredis-
eases.org) is a non-profit federation of over 100 volunteer 
organizations and 5000 patients and providers dedicated 
to helping people with rare diseases. The NORD web-
site posts information about active studies along with 
researcher contact information for patients and their 
physicians (at no cost),
21 and invites applications for seed 
funding for the study of new treatments and diagnostic Open Medicine 2012;6(1)e24
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Table 1 
International initiatives to promote research and development related to rare diseases
Region Policies / Measures Provisions
Australia 1997
Australian Orphan Drug Program5,6
•  Encourages rare disease drug registration and marketing by providing:
  — a waiver of fees for the application for orphan drug designation
  — a 5-year period of marketing exclusivity




Regulation on orphan medicinal products
•  Guarantees 10 years of market exclusivity for approved orphan products
•  Facilitates orphan drug registration by creating an EU-wide approval 
procedure
•  Calls for tax credits to be developed by individual member states7,8
2000
Committee for Orphan Medicinal Products
•  Monitors orphan-drug claims 
•  Improves patient access to orphan drugs across the EU
Framework Programmes (FPs)
•  1998–2002: FP5 
•  2002–2006: FP6 
•  2007–2013: FP7
•  Funded 47 rare disease projects (€64 million) 
•  Funded 59 projects (€230 million)
•  Funded over 50 projects (€237 million) between 2007 and 20109
2009
Council Recommendation on action in the fi  eld of rare 
diseases
•  Establishes coordination among Member States to utilize national 
resources and expertise to reduce inequalities in access to high-quality 




French National Plan on Rare Diseases
2011–14
French National Plan on Rare Diseases10
•  €7.9 million budget
•  €108.5 million budget8
•  Currently actively funding projects (budget to be determined)
Germany 2003–08
Research program on rare diseases
•  Funded 91 projects (€25 million)1
2010
National coalition for people with rare diseases (NAMSE)
•  Currently updating the German plan for rare diseases for 2011–1311
Japan1 1993
Japanese Orphan Drug Regulation
•  Provides fi  nancial incentives for rare disease drug development, 
including:
  — tax incentives
  — fast-tracking of drug evaluation
  — technical assistance for drug approval 
  — partial reimbursement of development costs 
  — an extended registration validity period6
  — a 10-year period of exclusive marketing for successful products
Singapore 1991
Orphan Drug Act12
•  Defi  nes orphan drugs and the legal framework for orphan drug imports
Spain 2003
Spanish Rare Diseases Research Institute
•  Promotes and carries out rare-disease clinical and basic research, 
provides training and support to health care providers, and funds 
innovation in patient care
2003–09 •  Provided funding for rare-disease research projects (€11.9 million)
(2003–04)1 
•  Created the fi  rst Spanish-language rare diseases information system
•  Included rare diseases among priority areas for the Spanish National 
Research Institute 
•  Established the Centre for Biomedical Network Research on Rare 
Diseases (2006) 
•  Created the State Reference Centre for Rare Diseases Patients and 
Families (2009)
2009
Spanish National Health System Rare Diseases Strategy 
approved
•  Targets medical professionals and patients with the general aim of 
improving health and quality of life for people with rare diseases (budget 
unknown)13
Taiwan1 2000
Rare Disease and Orphan Drug Act
•  Covers R&D, manufacturing, and acquisition for orphan drugs and pre-
vention, diagnosis and treatment of rare diseases, and drug subsidies
•  Includes a mechanism for a 70% to 100% drug and medical expense 
reimbursement for people with rare diseasesOpen Medicine 2012;6(1)e25
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tests for rare diseases.
22 Also, it was as a result of sus-
tained lobbying by NORD that the US Congress passed 
the Rare Diseases Act in 2002. In Europe, The European 
Organization  for  Rare  Disorders  (EURORDIS;  www.
eurordis.org)  represents  more  than  260  rare  disease 
organizations in more than 30 European countries and 
plays a role similar to NORD’s.
23 In Canada, advocacy is 
provided by the Canadian Organization for Rare Disor-
ders (CORD; www.raredisorders.ca). 
In contrast to the comprehensive and proven effect-
ive approaches developed by nations around the world, 
Canada remains one of few countries without policies to 
address research into rare diseases (including drug de-
velopment incentives) and drug access for patients. Since 
it came into existence in 2000, the Canadian Institutes 
of Health Research (CIHR) have seen an increase in their 
annual budget from around $350 million to nearly $1 
billion in 2009–10.
24,25 Yet it was not until 2011 that the 
first funding competition specific to rare diseases was 
announced, allocating a maximum of $14.5 million be-
tween 2012 and 2017, including commitments from part-
ner organizations.
26
Logically, a comprehensive strategy to address orphan 
disease research should be developed and legislated at 
the federal level, building and improving on processes in 
other developed nations. For example, a caveat to the US 
Orphan Drug Act is that it eliminates short-term market 
competition by guaranteeing drug developers 7 years 
of market exclusivity. Although this policy has success-
fully driven rare disease drug development, it has also 
been criticized for facilitating prohibitive drug costs. In 
Canada, it is possible to envision a federally sponsored, 
single-payer system to fund pharmaceuticals for rare 
diseases that includes a policy mechanism that would 
control costs through advance negotiations with drug 
developers while still maintaining market incentives. 
Furthermore,  provisions  of  the  US  Orphan  Drug  Act 
have resulted in drug development being carried out pre-
dominantly in the private sector in the United States, as 
opposed to government labs or universities.  This should 
also be addressed in a future Canadian policy through 
specific incentives to encourage drug development in the 
non-profit sector.
The first step toward a Canadian policy was a Private 
Member’s motion brought before the House of Com-
mons in 2008 by Don Bell, then Member of Parliament 
for North Vancouver.
27 This motion called on the fed-
eral government to examine the feasibility of creating 
a Canadian Rare Disease Strategy that would emulate 
the principal components of the EU’s strategy. Meas-
ures proposed by the motion included creating a fund 
for nation-wide drug coverage for rare disease suffer-
ers, developing Canadian Centres of Reference for rare 
diseases, and providing public and private organizations 
Table 1, continued
United States 1982
FDA Offi   ce of Orphan Products
•  Promotes development of products for the diagnosis and/or treatment 
of rare diseases
•  Funds clinical research through the Orphan Products Grants Program14 
•  Administers the major provisions of the Orphan Drug Act
1983
Orphan Drug Act
•  Creates fi  nancial incentives for academic institutions and manufacturers 
to engage in rare-disease drug development, including:
  — tax credits for costs of clinical research
  — a waiver of certain fees involved in new drug applications
  — direct FDA grant support
  — assistance for clinical research
  — a 7-year period of exclusive marketing for successful products2
2002
Rare Diseases Act
•  Provided for a new grants network for research on rare diseases
•  Developed regional centres of excellence for clinical research and 
training in rare diseases 
•  Supports research in diagnostic tools for patients with rare diseases15
2003
National Institutes of Health Rare Diseases Clinical 
Research Network
•  Consists of a central data and technology coordinating centre with 10 
disease-based research consortia2,16
•  Currently studying over 40 rare diseases at 70 sites
Multinational 2008
European Project for Rare Diseases National Plans 
Development (EUROPLAN)
•  30 partners (all 27 EU countries, USA, Turkey and the patient organization 
EURORDIS)
•  Ensures access to prevention, diagnosis, treatment and care through 
the production and dissemination of data and recommendations for 
developing plans or strategies for rare diseases in individual member 
states17
Note:  All programs/policies without an end date are still in place.
FDA = US Food and Drug AdministrationOpen Medicine 2012;6(1)e26
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with incentives to undertake rare disease research, in-
cluding drug development. Although the motion was 
passed,
28,29 no sustained debate, feasibility assessment, 
or measurable government action has since materialized.
A call to action
The imminent renewal of the federal-provincial Health 
Accord, which expires in 2014, presents an opportunity 
for provisions for a federally designed rare disease strat-
egy to be tied to provincial funding, with an accountabil-
ity structure to measure progress. Although the current 
federal government has delineated the financial terms 
of the future Accord, at the time of writing, discussions 
around national standards and provincial accountabil-
ity have yet to occur.
30 To this end, the Canadian med-
ical and scientific communities should lobby both the 
federal government and the CIHR directly for action. 
This can be achieved through free advocacy programs 
offered  by  the  Canadian  Medical  Association  (CMA), 
such as the MD-MP Contact Program, which matches 
CMA members with their local Member of Parliament. 
Furthermore, the CMA should prioritize this issue, pre-
senting a unified front to the federal government. These 
efforts should be made in conjunction and consultation 
with CORD, which represents a large number of rare dis-
ease groups—a strategy that has proven to be effective in 
driving political change in other jurisdictions. Individ-
ual stories of rare disease sufferers being denied expen-
sive drug coverage also routinely ignite fierce public calls 
for government to institute more compassionate policies. 
Increasing public awareness of the overarching need for 
a centralized rare disease policy could also stimulate 
an effective grassroots movement. Strategies to educate 
and engage the public include direct discussions with 
affected patients, their families, and their friends (who 
should be encouraged to contact their MPs), promoting 
activities by rare disease advocacy groups (e.g., “Rare 
Disease Day in Canada 2011,” organized by CORD), and 
participating in awareness campaigns in mass-media 
publications and in social media (e.g., a 2011 Globe and 
Mail series highlighting the plight of Canadian rare dis-
ease sufferers).
31
In the interim, or failing a federal solution, those who 
suffer from rare diseases and their advocates might turn 
to provincial governments to lead the development of 
rare disease programs. However, given our geographic-
ally dispersed population and the need for multicentre 
participation  to  recruit  sufficient  numbers  of  partici-
pants to rare disease studies, interprovincial partner-
ships for rare disease research funding, recruitment, 
and resource and expertise sharing will be required. 
Challenges include the wide range of political parties 
represented across provinces, their correspondingly 
eclectic health care priorities, and their various fiscal 
positions. However, these disparities would seem to pale 
in comparison with those between the 30 countries that 
have successfully instituted and currently uphold the 
many binding EU-wide legislative  requirements and 
programs related to rare diseases. This suggests that a 
lack of political will may be the only barrier to success. 
In this era of limited health care resources, a utilitar-
ian approach to wealth distribution would argue that 
substantial resource investment in rare diseases fails to 
maximize the benefit to society by bringing the greatest 
good to the greatest number. However, the “paradox of 
rarity” is that, given the existence of over 6000 known 
rare diseases and the fact that 6% to 8% of the popula-
tion is affected by a rare disease, even though each dis-
ease is rare, patients with rare diseases are many.
23 
Based on a belief that our society’s moral obligation is 
to protect each individual’s rights, the Canada Health Act 
upholds the principle of “non-abandonment,”
7 whereby 
all Canadians should have “timely access to health ser-
vices on the basis of need, not ability to pay ” and “the 
health care services available to Canadians are of high 
quality, effective, patient-centred and safe.”  Far beyond 
the simple question of access to drugs, a right to effect-
ive and high-quality care can not be fulfilled without 
addressing the fundamental gap in access to scientific 
advancement and research in rare diseases. 
It is our duty to advocate for these patients by calling 
on our political leaders to join the rest of the developed 
world in legislating a comprehensive strategy to improve 
Canadian orphan disease care and research. 
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